Vaxart, Inc. (VXRT) Earnings Call Transcript & Summary

November 6, 2026

OTC Pink Market US Health Care Biotechnology earnings 61 min

Earnings Call Speaker Segments

David Carey

executive
#1

Thanks for joining us this afternoon. On the line from Vaxart we have Steven Lo, our Chief Executive Officer; Mark Watson, Lead Independent Director and a member of the board's Stockholder Engagement Committee; Dr. Rocky Bono, Independent Director and Chair of the Stockholder Engagement Committee; Dr. Sean Tucker, Founder and Chief Scientific Officer; Dr. James F. Cummings, Chief Medical Officer; and Jeroen Grasman, Chief Financial Officer. To start, I'd like to remind everyone that during today's call Vaxart might issue forward-looking statements. These could cover the company's financial results and financial guidance, its future business strategies and operations, partnerships with third parties, the timing of anticipated regulatory milestones or clinical data readouts, its future cash runway, the ability to raise capital, and progress on product development. Quite a few important factors could make actual results differ materially from what these forward-looking statements discuss, among them the uncertainty that is inherent in clinical development and regulatory processes, along with other risks laid out in the risk factors section of Vaxart's most recently filed annual report on Form 10-K and in periodic reports filed with the SEC. Vaxart isn't committing to revise any forward-looking statements once today's call has ended. At this point I'll hand things over to Steven Lo. Steven?

Steven Lo

executive
#2

Thank you, David. Good afternoon to all of you, and we appreciate your joining us today for our third quarter 2026 fireside chat—the fifth quarterly fireside chat and the sixth overall fireside chat that we have hosted; these discussions form a key part of our continued commitment to keeping transparency and visibility for our stockholders. For Vaxart, the third quarter and the recent weeks have been a productive stretch across our clinical programs, pipeline validation, and corporate governance. Executing the main cohort of our Phase 2b COVID-19 trial remains our primary operational focus. After the encouraging 12-month head-to-head safety data from our 400-participant sentinel cohort that we reported in July, our clinical operations and trial site teams have been actively moving the approximately 5,000-participant main cohort forward. We expect to report efficacy and safety data by mid-year 2027. Beyond our clinical momentum, we have taken important steps to strengthen our board leadership and corporate oversight. To say more about our governance initiatives and to introduce our newest director, I would like to hand the call over to our Lead Independent Director, Mark Watson. Mark?

Mark Watson

executive
#3

Hello, everyone. I'd like to take a moment, on behalf of the whole board, to speak directly to you, our stockholders, with acknowledgment and thanks. The support you keep giving us and the engagement you maintain are essential to all that Vaxart does. We appreciate the perspectives that you bring to us and anticipate carrying that conversation forward in the time ahead. With that in mind, our board has set up a dedicated Stockholder Engagement Committee made up of Steven, me, and Dr. Bono, our newest independent director, a retired Vice Admiral of the US Navy. This committee gives us one more setting for direct exchange between the board and our shareholders, making sure that investor feedback shapes how we oversee the company's strategy and execution. We're glad that Dr. Bono is serving as chair of this committee. She has also joined the Clinical and Regulatory Affairs Committee and the Nominating and Governance Committee. Rocky has an outstanding record of leadership in military surgery and public health, having served as a three-star Vice Admiral in the US Navy and as former director of the Defense Health Agency. Her emphasis on operational discipline makes her the ideal person to lead our engagement efforts and an ideal member of this board. I'd like to ask Rocky to say a few words. Rocky?

Rocky Bono

executive
#4

I appreciate that, Mark, and good afternoon to all of you. Over the course of my career — as a Navy trauma surgeon, in my role leading the Defense Health Agency, coordinating Washington state's health system response during COVID-19, and directing global health operations for Viking Cruises — I have witnessed firsthand where traditional needle-based vaccines fall short. That operational reality explains why my belief in Vaxart's mission is so strong. Leading large-scale military and public health organizations has also deepened my appreciation for trust, accountability, and open communication. In my view, effective governance is essential to success, and it begins with listening, posing the right questions, and making sure differing viewpoints get weighed when decisions are made. Those principles will sit at the center of how I approach my role as chair of the Stockholder Engagement Committee. My plan is to fully integrate stockholder perspectives into our board discussions, helping keep the board tied to these priorities as we oversee management's execution of Vaxart's strategy and strive to build lasting value. I'm eager to engage directly with our stockholders and to work with the whole board in support of Vaxart's long-term success. With that, I'll turn the call over to our Chief Medical Officer, Dr. James Cummings, who will walk through our clinical updates. James?

James F. Cummings

executive
#5

Thanks, Rocky — good to have you with us. Before I get into the COVID-19 update, I'd like to flag two noteworthy items elsewhere in the pipeline. First, norovirus: at the end of August this year, the European Patent Office issued a patent carrying protection for our oral norovirus vaccine technology out to at least 2036 in 13 countries across Europe. That dovetails neatly with the US patent estate we already hold. Together, they provide IP protection across multiple jurisdictions through 2036, and that is now part of the data package supporting ongoing talks with prospective partners. Second, H5N1 avian influenza: in early October, we published peer-reviewed data demonstrating 100% protection against a lethal H5N1 avian flu challenge in a ferret model. When it comes to pre-clinical research on human respiratory infection, the ferret is broadly regarded as the gold standard. What this study demonstrates is the agility and modularity of our VAAST oral platform, which highlights how we are able to engineer and deploy vaccine candidates against high-consequence emerging threats with real pandemic readiness. Now, moving to our Phase 2b COVID-19 trial, among the questions we receive most frequently is one about the clinical timeline — in particular, what actually goes into conducting a study of this magnitude and why it takes the time that it does. To give you a clearer picture, I want to break down what a study of this magnitude and intricacy actually involves, so it becomes obvious why a careful, methodical strategy is essential for producing reliable data that will satisfy regulators. Start with the sheer operational footprint. This isn't some modest early-stage safety study with 30 or 40 volunteers. What we're running is a broad, direct-comparison trial pitting our oral tablet vaccine candidate against an approved mRNA shot, enrolling roughly 5,000 active participants across 140 sites around the country. Standing up that footprint, ensuring each location follows rigorous clinical requirements to the letter, and keeping data collection at regulatory quality consistent across thousands of enrollees — that demands a great deal of coordination. Also, screening is rigorous. Our clinical teams must evaluate many thousands of people to get 5,000 qualified participants enrolled. Since this study assesses comparative immune responses and real-world infection endpoints involving the KP.2 variant of COVID-19, each participant has to meet tight protocol requirements concerning vaccination history and prior infection. Proper participant screening takes time, and it keeps our final dataset uncompromised and ready for regulatory scrutiny. And third, required observation periods fundamentally govern clinical timelines. To measure vaccine efficacy, durability, and mucosal as well as systemic immune responses accurately, participants are followed across set protocol windows that span months. Such observation periods are essential for understanding how the immune system builds and maintains protection over time. After that, the clinical and lab results have to be reviewed and source-validated before they can be finalized, and for a study of this magnitude that process stretches over several months. Then, when all patient visits are done, thousands of mucosal swabs and blood samples still need standardized lab processing, assay validation, rigorous quality checks, and regulatory data locking—all of which must happen before unblinding can occur. Much of the immunologic and viral lab testing for this trial is carried out by laboratories that are BARDA partners, which helps ensure a standardized approach and a more cost-effective path for a program this large. Because those labs operate separately from Vaxart, their testing and processing schedules depend on their own timelines and on coordinating with BARDA. We're working very closely with the many partners to manage these dependencies and keep the program moving forward in a very timely way. Running under Project NextGen with BARDA has provided Vaxart the non-dilutive resources required to conduct a study of this scope and magnitude. As a federal government partner, we also have to follow regulatory schedules as well as BARDA's established review processes and oversight timelines. For a study of this scale aimed at federal partnership and regulatory submission, rigorous execution and alignment with federal requirements must remain the priority. We've already cleared several key checkpoints, including the clean 12-month safety clearance from our sentinel cohort of 400 participants. As we work through the remaining follow-up windows, the team remains fully focused on delivering the readout by mid-year 2027. With that, I'll turn the call over to Jeroen for our financial update. Jeroen?

Jeroen Grasman

executive
#6

Thanks, James. Now I'll walk through the financial results for the third quarter of 2026. On cash position and runway: as of the end of the third quarter, Vaxart held $65.5 million in cash, cash equivalents, and short-term investments. Based on the operating assumptions we hold at present, we still expect this balance to fund our operations into the second quarter of 2027, and we continue to evaluate every opportunity to extend that runway. On the revenue side, total revenue for the third quarter was $10.6 million, compared with $72.4 million in the third quarter of 2025. Revenue recognized during the period came primarily from work performed under our BARDA Project NextGen contract, along with continued revenue recognition related to our collaboration agreement. On the R&D side, research and development expenses were $22.8 million for the third quarter, versus $75.9 million in the same period of 2025. Clinical trial spending largely reflects the work we are doing to execute the Phase 2b COVID study. Turning to general and administrative costs, G&A expenses were $5.1 million for the third quarter, compared with $4.3 million in the same quarter of '25. And finally, on net loss: we reported a net loss of $17.7 million for the third quarter, or $0.04 per share, versus a net loss of $8.1 million, or $0.07 per share, in the third quarter of 2025. In addition, through September 30th of 2026, we brought in $0.5 million from shares issued and sold under the April 2026 share purchase agreement with Lincoln Park Capital. The remaining portion of the $25 million commitment under that share purchase agreement stays available to us as a flexible capital source, entirely at our discretion. We remain committed to strict financial discipline and continue to explore partnerships, grants, and other non-dilutive funding mechanisms as we move toward our major clinical readouts. I'll hand the call back to David now so we can begin the Q&A session. David?

David Carey

executive
#7

Thanks, Jeroen. We will now start the Q&A session, and like on earlier calls, we have gathered questions that stockholders sent in ahead of time, which we have sorted by topic, and we will also be watching submissions come in live through the webcast portal. To start, Steven, I will put this question to you. Do you believe the recent election results will have an effect on funding for the COVID-9 for the COVID Phase 2b trial, or on when the full trial results will be released?

Steven Lo

executive
#8

Thanks, David, and I appreciate the question. We aren’t expecting any changes at all. Put simply, no. Just to remind everyone, this trial was originally awarded while a democratic administration was in office, and afterward, during the trial, it moved to a republican administration, and I believe stockholders recognized that in 2025 we received two stop-work orders, and we managed to get past them and keep the trials going. From where we sit, we’re glad to be, honestly, the sole company that made it through those stop-work orders. Many other vaccine companies got them and haven’t gone on to complete a trial. From our perspective, we truly value our tight working relationship with BARDA. We’re grateful for their partnership, and we keep collaborating with them to bring this trial to completion.

David Carey

executive
#9

Thanks, Steven. James, the next question goes to you. You had said the full data readout from the Phase 2b COVID trial would come in the first half of 2027. Now the expectation is mid-2027. Could you walk us through the reason the timing has been updated?

James F. Cummings

executive
#10

Thanks, David, and I appreciate the question. Absolutely. As I covered a short time ago, whenever you are running a registration-trial quality clinical study on this scale—around 5,000 active participants enrolled nationwide—the schedule is really shaped by deliberate protocol requirements, not by some arbitrary interval. To repeat, the three main factors that control the calendar are the protocol-defined observation windows, and since this is a comparative efficacy trial, you essentially cannot compress biological time. Participants must be followed across set multi-month observation windows so that real-world variant infection endpoints can be evaluated and both mucosal and systemic immune response durability can be measured. I touched on some specifics regarding laboratory processing and assay validation. After those visits and sample collections finish, thousands of mucosal swabs and blood samples go through centralized laboratory processing, rigorous assay validation, and formal regulatory data locking before any unblinding is possible. It's worth noting that this sample processing takes place at BARDA's partner labs, and those labs determine the timing and the prioritization of our samples alongside the work they perform supporting other trials and programs for BARDA. Federal governance and review alignment is another element here. Running this study under Project NextGen means coordinating closely with our partners at BARDA; we must follow federal oversight and the review processes that come as part and parcel of that partnership, making sure the dataset satisfies BARDA program goals along with every agency standard for regulatory review. Thank you.

David Carey

executive
#11

Thanks, James. Sean, the next question is yours. Although the top-line safety and side effect profiles from the sentinel group were impressive, investors want to see the underlying data, such as immunogenicity, viral load, shedding, and severity of infection. Has this more detailed sentinel data been seen yet by Vaxart, BARDA, Sanofi, or any other entity? And what about detailed full Phase 2b data? The second part of this is, given the long wait expected for the full Phase 2b data, which is now in mid-2027, can shareholders at least expect more detailed sentinel data to be shown before the end of the year? If not, is BARDA withholding it, or is it Vaxart's decision to withhold it?

Sean Tucker

executive
#12

Thanks, David, for that question. To answer you straight: no data is being held back by Vaxart or by anyone outside the company. Under contract modification number seven, the study samples went to an independent lab, or actually two independent analytical laboratories, for processing. Since those assays are run externally, we cannot forecast precisely when the labs will finish their analysis and hand over the data. We have not seen the underlying immunogenicity data, and neither has anyone else. On top of that, our contractual framework makes any public release of these results, and its timing, strictly dependent on BARDA's formal review and approval. We get the desire for detailed sentinel readouts before year-end, and we are certainly as anxious as you are; but we cannot commit to a specific release date until the lab data is finalized, delivered, and cleared for disclosure through the partner protocols we have established.

David Carey

executive
#13

All right, thank you Sean. James, this is somewhat like the earlier question, though I'll put it to you too. You said before that more data cuts would be shared. What's the timing on that?

James F. Cummings

executive
#14

Well, thank you, David. These detailed analytics are being actively pushed forward by us. That said, we aren't able to give a specific timeline for reporting, as Sean said, for further interim data cuts at this moment. Under our contract with BARDA, that agency holds authority over every trial readout. Whatever disclosure timeline exists depends on that collaboration and approval process continuing. A strong and positive working relationship with the people at BARDA is something we continue to maintain, and we value their ongoing partnership as this program moves ahead with all of us together. As for overall trial milestones, we look forward to sharing efficacy and safety data from the main study cohort by mid-year 2027. Over to you, David.

David Carey

executive
#15

Thanks, James. Sean, I have another question for you: could you give us more detail on the XBB immunology data and explain what it tells us about the mucosal and systemic immune response?

Sean Tucker

executive
#16

Thanks, David, for asking that. Like we said earlier, we still don't have clinical immune data on XBB, so we're unable to discuss it. What I can say is that in animals, we know the vaccine was immunogenic.

David Carey

executive
#17

Appreciate that, Sean. Steven, handing it back to you. A lot of our shareholders still feel that a norovirus vaccine would rank among the most valuable advances for both this company and the stock. Could you give us an update on where things stand regarding partnering?

Steven Lo

executive
#18

Absolutely, and it seems a handful of other questions have just come in that tie very closely to this. I appreciate everyone asking about where things stand with the norovirus partnerships. Let me lay out three points. First, we're working through wider biopharma market headwinds, and a lot of the partners we've been talking with are tightening how they allocate capital. They've had to contend with matters like most-favored nations, etc. They're stretching out diligence timelines somewhat, and they're becoming more selective as well. That said, interest in our norovirus Phase 2-ready candidate does exist and continues to exist, and we're holding conversations with potential partners. Beyond that, with global public health entities, government stakeholders, etc, we're working to secure a structure that moves norovirus forward without, naturally, sacrificing any long-term value for the company. Third, should we wind up with nobody interested remaining at the table at all, we will of course make that clear to the shareholders instead of dragging out your expectations. We do have non-disclosure agreements in place, along with the SEC requirements that keep us from sharing interim negotiations or even naming the companies we're speaking with. Please rest assured that advancing norovirus and finding a way to fund it stays among the top priorities for the leadership team, and we will definitely share significant updates once we have definitive agreements reached. Once again, thank you, everyone, for the interest there.

David Carey

executive
#19

All right, thank you, Steven. Sean, I have one more question for you. Could you give us additional detail on what the norovirus European patent means for Vaxart's business? Is there any commercialization plan set up for Europe, and in what way could this move your partnering efforts forward?

Sean Tucker

executive
#20

David, I appreciate the question. Back in August of 2026, the European Patent Office granted a patent that covers Vaxart's needle-free, room-temperature stable tablet vaccine technology directed at norovirus. We believe there is enormous worth in making sure our intellectual property stays protected, and it likewise helps guarantee that this oral vaccine can reach people around the world. Europe, naturally, is the second-biggest market after the United States, which makes it a strategically vital territory for our portfolio as we pursue wider commercialization on a global scale. This patent broadens our worldwide intellectual property portfolio and carries protection forward through at least 20 2036 in 13 European countries. Those include major markets such as Germany, France, Italy, Spain, and the UK. It additionally dovetails neatly with the US patent estate Vaxart already holds, producing patent protection across multiple jurisdictions.

David Carey

executive
#21

Thanks, Sean. Here's another one for you. Management said before that the GII.17 strain being dominant was a hurdle for partners. The newest CDC CaliciNet figures appeared to reveal precisely the turnaround those partners had been hoping for. Through September 2026, in the most recent reporting period, GII.4 Sydney has climbed back to roughly 46%, whereas GII.17 has fallen to 17.5%. Since GII.4 is the top reported norovirus genotype once again, has this shift produced any real movement in those conversations? And should shareholders look for any cross-reactivity data on GII.4 or GII.17 anytime soon?

Sean Tucker

executive
#22

Appreciate the question. The prevalence of strains keeps shaping the conversations we’re having with possible partners on the norovirus program. The move toward greater GII.4 prevalence could perhaps strengthen the program’s value proposition, simply because we hold clinical data for GII.4, though we haven’t yet evaluated the GII.17 strain in the clinic. That said, Vaxart can add strains quickly when needed. We haven’t observed interference in animal studies or human trials, and adapting our platform for each new antigen is relatively straightforward. Another point, naturally, is that a key strength of our norovirus vaccine is that cross-reactive immune responses to many GII strains have been seen in adults. A portion of those data was presented in 2025 at the Calicivirus Conference.

David Carey

executive
#23

Thanks, Sean. Steven, here's a question for you: how far has management gotten on landing a pharmaceutical partnership that really matters, a licensing deal, or a strategic transaction?

Steven Lo

executive
#24

When it comes to meaningful partnerships with pharmaceutical companies and license agreements, I'd note that over the past two years we have in fact achieved some significant progress. For instance, we signed an exclusive worldwide license agreement with Dynavax covering our COVID vaccine program. We obtained $25 million upfront plus a $5 million direct equity investment made at a premium to the market price. Going forward, if Sanofi decides to opt in, given that they acquired Dynavax, we stand to receive as much as $670 million across future clinical, regulatory, and sales milestones along with tiered royalties; that is clearly a very meaningful partnership for us, because in addition, this is a study we set up through a partnership with BARDA under Project NextGen, which provided hundreds of millions of dollars in non-dilutive clinical funding to bring us to the point where we are nearly at the clinical trial results in mid-2027. Those certainly illustrate the meaningful partnerships and agreements the company has signed over the last two years. Outside of COVID, as we discussed earlier, the leadership team is actively engaged in conversations with pharmaceutical and global health stakeholders about possible partnerships for norovirus. As an illustration of how strongly we believe in the value of norovirus, as Sean mentioned, we made the investment to prosecute the patents in Europe, because if a global partner is interested, seeing that we hold patent protection through 2036 is also very meaningful; we are investing in our pipeline and are specifically and actively seeking a reasonable partner for the norovirus program.

David Carey

executive
#25

Alright, thanks Steven. Steven, here's one more question for you: has Vaxart put in a proposal for BARDA's NPIVS program, or are you thinking about doing so?

Steven Lo

executive
#26

As I mentioned earlier, we have a really strong working relationship with BARDA, and that keeps the lines of communication open. The management team constantly keeps watch, and we pursue non-dilutive grants and partnerships with other agencies quite aggressively, across respiratory and pandemic preparedness indications. Clearly, this is a solid way to support our clinical pipeline, as you have seen with the COVID study. At the same time, we want to stay very mindful about being capital-efficient, and we spend considerable time reviewing all of these opportunities. Whenever any of these contract awards or new federal partnerships get announced publicly, we adhere to our disclosure requirements. We don't publicly say what we apply for or when, since we don't want to harm our odds of winning the award, because often that can have an impact. Beyond that, given that we operate in a competitive environment, we don't want to share information such that a competitor learns right now about a very similar grant and then they end up applying for it too. Those are the reasons we may not go into specific details, but I do want to say that we keep watch on all of them. We are very diligent, and we are certainly aware of all the opportunities out there. Thanks for reminding us of that.

David Carey

executive
#27

Alright, thank you, Steven. Here's a question that just came in through the portal. Jeroen, I'll send this one your way: at what point do we anticipate the milestone payments from Altesa?

Jeroen Grasman

executive
#28

Thanks, David. And just to give everyone on the call some background, I suppose, the Altesa reference relates to an out-license agreement we struck for one of our assets back in the day, a company called vapendavir; it's a clinical-stage, broad-spectrum antiviral that Altesa is developing, and it's currently in a Phase 2b study. The agreement provides, and I guess as we disclosed in 2021, for roughly $130 million, up to $130 million in development and commercial milestones, along with tiered royalties. Now, clearly, this program isn't under our control. Altesa is the one developing it. It's in Phase 2b. None of the milestones are due at this time. As the question is around timing, since we don't control the study ourselves, it's impossible for me to speculate on the timing of advancement, and we haven't previously disclosed what exactly triggers those milestones, and I'm not going to do so now. Clearly, it's a great question, at least make everybody aware that that's something that is actively in development and there's potential future dollars due to our company.

David Carey

executive
#29

Thank you, Jeroen. Steven, handing it back to you. Has the Sanofi relationship grown past COVID into talks about Vaxart's wider platforms, like influenza, norovirus, or any other assets?

Steven Lo

executive
#30

With our existing Sanofi agreement — and just to remind everyone, Sanofi picked this up when they bought Dynavax, the company we originally signed the COVID-19 collaboration and licensing deal with — that covers only the COVID-19 vaccine program. We actually engage with Sanofi quite a lot, including through our regular Joint Steering Committee meetings, but their entire focus is on the Phase 2b study and on delivering a strong clinical data package so we can make sure there's a high chance of opt-in. As a reminder to stockholders, should Sanofi opt in, that triggers a $50 million payment to the company. I think you can picture why we devote so much time to making sure we build that relationship, while also executing on this study, as James highlighted very well. Now, given how closely we work with Sanofi, it's fair to say they are growing more and more aware of our platform and the science behind it, which Sean walked through, and from that angle, I can tell you they are certainly aware of the other programs we have in the pipeline.

David Carey

executive
#31

Thanks, Steven. Actually, here's another one for you: as far as you're able, could you give shareholders a clearer view of the partnership talks and non-dilutive funding discussions currently underway?

Steven Lo

executive
#32

Sure. I believe I've addressed a question quite like that one before, but I'll definitely go into a bit more detail on it, right? We're constantly on the lookout for,

David Carey

executive
#33

yeah,

Steven Lo

executive
#34

We see opportunistic ways to use our platform so it creates more value. As for our current priorities, we want to carry out the Phase 2b COVID study, as I mentioned earlier. A $50 million opt-in payment would be nice, so we want to do this properly and execute it the right way together with our existing partner, BARDA, and hopefully we'll have a great partner in Sanofi. That said, we keep searching for other non-dilutive funding opportunities, as the team mentioned earlier, whether from government agencies, and those include agencies outside the United States; we talk with global pharma companies. We also talk with regional pharma companies. We examine territories outside the United States; we examine the United States, of course, and then we also examine the European territory, as shown by, once again, the work Sean and our IP team have done to secure patents for norovirus in Europe. Those are the kinds of discussions we have; for obvious reasons, once we enter deeper discussions, we have to go under an NDA, a non-disclosure, and that therefore prevents us from naming companies and, of course, from providing any details about them. Please be assured that if we obviously end up in a very good situation where a deal is signed, we will disclose that right away, very similar to what we did when we disclosed our deal with Dynavax last year.

David Carey

executive
#35

Appreciate that, Steven. Sean, handing it back to you. Has there been any thought given to going after additional indications for the oral vaccine platform beyond COVID, noro, and the like?

Sean Tucker

executive
#36

Appreciate the question. Yes is the short answer. I believe everyone knows we have a therapeutic vaccine for HPV in development, and we've published data on it from a pre-clinical standpoint. Another point you might not know is that several years back, we got NIH funding in order to evaluate our platform against Venezuelan equine encephalitis virus. That's one example of what non-dilutive funding let us accomplish, moving forward not only this indication but our platform too. Of course, bear in mind that we're always optimistic about ways to use our platform to generate additional value or secure non-dilutive funding that advances current or additional programs. That being said, starting or expanding any new indications stays strictly dependent on obtaining appropriate funding or strategic support. As we've said before, our current priorities are executing the Phase 2b COVID trial and securing a partner on funding for the norovirus program.

David Carey

executive
#37

Thanks, Sean. So Steven, once we get past the COVID readout in mid-2027, what does the current plan look like for Vaxart?

Steven Lo

executive
#38

Right. The first item, like I said before, involves the COVID readout — we're aiming to put a lot of effort into getting the Phase 2 package submitted to the FDA, and naturally Sanofi will be looking at those results at that stage too. We really want to make sure there's an opt-in along with a $50 million payment. That naturally involves drawing on support from our partner BARDA and getting to a strong position where Sanofi feels confident this represents a substantial opportunity within their pipeline. Past that — and I think this illustrates well our view that the remaining assets in our pipeline matter — a readout for one asset frequently lets others carry higher confidence. It's interesting, and we're getting questions about what we're considering doing with flu, for instance, correct? A positive readout in a respiratory virus such as COVID actually gives other partners or other funding sources more confidence to say they believe in flu as well. In a sense, that's a strategy tied to a particular portfolio. As we discussed earlier, we're putting a lot of effort into advancing what we can toward getting norovirus funded. Once again, that's typically non-dilutive, and partnerships are where we begin. Another point I'd add is that as we keep succeeding, we're building more experience with the platform. Sean, of course, and his research team have created some excellent opportunities with the second-generation construct and other areas. When the Phase 2b trial ends, consider this: we will have dosed over 6,500 subjects with our oral vaccine platform, and from where I sit, that also gives any other parties out there who might want to partner with us greater confidence.

David Carey

executive
#39

Thanks, Steven. Sean, I’ll send the next question your way: which measurable accomplishments can management cite that have generated tangible shareholder value across the last few years?

Sean Tucker

executive
#40

Thank you again for raising that. Speaking as the investor who has held Vaxart shares longer than anyone else, I want to assure you that we are putting tremendous effort into building shareholder value with the resources we have. Management does understand that real, tangible value for shareholders ultimately is reflected in how the market values the company, yet for the last several years our central mission has centered on lowering risk and moving our mucosal vaccine platform forward. To illustrate, we devoted enormous effort to drafting proposals that would not dilute shareholders, and we take real pride in having obtained the landmark non-dilutive funding award via Project NextGen. BARDA is covering the entire cost of our large-scale comparative COVID-19 trial and permitting us to enroll substantially more subjects, which allows us to produce strong, meaningful data. After that, we turned it into a licensing arrangement with Dynavax — and again, that unfolded across the past several years — which delivered $25 million in extra non-dilutive funding along with a $5 million equity investment priced at a premium to where our stock was trading. Had funding for that COVID-19 study not come through, the company would at that moment have lacked the money to push any clinical studies forward, leaving us in an extremely dire financial spot. To keep the company alive, leadership made decisive operational moves aimed at protecting liquidity — shrinking the organization, applying budget cuts across every area, and optimizing our real estate footprint so we could sharply lower cash burn while continuing to move our bivalent norovirus program ahead. What we've done here confirms the strength of our oral platform by way of top-tier federal collaborations, has let us grow our clinical evidence base while limiting dilution for shareholders, and has put in place the efficient operating and financial base we need in order to create durable enterprise value over the long run as our trial endpoints reach maturity.

David Carey

executive
#41

Thanks, Sean. Steven, the next question is for you: could you walk us through how the evaluation process worked to identify the seventh independent director? What criteria were used?

Steven Lo

executive
#42

Absolutely, we're glad to welcome Dr. Bono onto our board of directors. Her appointment came about through the cooperation agreement Vaxart signed with the stockholder group, and that was back in July of this year. This was a joint effort with the stockholder group, and I truly want to thank them for the way they engaged and for the ideas they brought forward. They and Vaxart each put forward nominees, and we reviewed those nominees as a group. Working together, we searched for someone who brings deep operational experience, leadership ability, and public health expertise. As you can see, Dr. Bono fits those criteria, particularly given her outstanding record as a three-star Vice Admiral in the US Navy, former director of the Defense Health Agency, trauma surgeon, former director of health systems response and global health operations for the state of Washington during COVID, and also Viking Cruises. Both the stockholder group and Vaxart chose her together.

David Carey

executive
#43

Steven, a follow-up to that: who else did the group consider, and what made Dr. Bono the strongest candidate?

Steven Lo

executive
#44

We looked at quite a few candidates, and while we can't disclose who they were, there were many highly qualified people in the mix, and once again, the decision was made jointly. I also want to thank the stockholder group once more for collaborating so closely with us. There were numerous meetings, and throughout that close collaboration they were genuinely focused on what would serve stockholders best. As I mentioned, Dr. Bono's background — I believe her credentials make the case on their own that she is clearly the strongest person to be joining the board, and I know she is eager to engage with and work alongside the Stockholder Engagement Committee.

David Carey

executive
#45

All right, Steven, here's another question for you. With the board leadership having been reorganized recently and new oversight committees now in place, has anything specific in the way of charter mandates been handed down to look at capital market strategy, how executive compensation lines up, and what strategic transaction alternatives might exist?

Steven Lo

executive
#46

When you look at capital market strategy, aligning executive compensation, and strategic transactions, those really all fall under what the full board oversees, and certain initiatives will be delegated to committees. For instance, aligning executive compensation sits with the board's Compensation Committee. We changed the chair of that committee not long ago, and Dr. Jim Breitmeier now serves as chair of the comp committee.

David Carey

executive
#47

Alright, here's another one for you, Steven: is the Compensation Committee making changes to executive bonus structures, stock options, and equity grants so that leadership payouts are tied strictly to clinical milestones and market cap performance?

Steven Lo

executive
#48

Correct, the Compensation Committee reviews every element — the company's goals, the corporate goals, the performance metrics for each person on the management team, and the company as a whole — and then ties compensation to the metrics that our board of directors ultimately approves.

David Carey

executive
#49

Thank you, Steve. I have one more question for you: under the stockholder agreement, the two sides agreed to create a Shareholder Advisory Council. Will membership be restricted to the stockholder group members only, or will other shareholders be able to ask to be considered for a seat as well? Steven, would you like to respond to that?

Steven Lo

executive
#50

Absolutely. Under the cooperation agreement, the exact term used is a Stockholder Engagement Committee, and Dr. Bono serves as its chair. I would definitely say that we are strongly committed to hearing from more than just the stockholder group that signed the cooperation agreement with us, and you can see that in our taking questions here and holding a fireside chat. Having a constructive, open dialogue with our whole investor base is genuinely what we want. The cooperation agreement does state that meetings and conversations will take place with that group. Our hope, and something we would definitely encourage, is that the discussion extends past that stockholder group. I have full confidence that Dr. Bono has been thinking this through, and we are working very closely with her on the best way to engage folks. As evidence that she is listening in and taking part here in this fireside chat, you can tell that she, together with Mark Watson, another member of our Stockholder Engagement Committee, were committed to making sure we get input from as many shareholders as possible, and we will keep involving as many as we can, just as we are doing here. Okay.

David Carey

executive
#51

Appreciate that, Steven. Here's another one for you: in what way does the committee intend to rank the input coming in from shareholders, and how will it make sure that input turns into substantive conversations at the board level?

Steven Lo

executive
#52

Yes, we’re making use of every avenue here, as an example, right? A lot of the questions are coming in. We put them into groups, and we get a sense of which themes are emerging. We go through the emails that arrive, and we’ll also hold the Stockholder Engagement Committee meeting. We’re genuinely bringing in all of that feedback, and together with the stockholder group this will help us prioritize which discussions are the important, meaningful ones we need to have. The stockholder group will supply the input, and naturally, by giving that input to the committee, it reaches the board level.

David Carey

executive
#53

Thanks, Steven. Jeroen, here's a question for you: given that our cash runway extends into the second quarter of 2027 and the Phase 2b readout is expected in mid-2027, how does management intend to bridge through that readout and the potential Sanofi decision while keeping dilution to a minimum?

Jeroen Grasman

executive
#54

Thanks. That's an excellent question, and I'm sure it's top of mind for our shareholders as well. Really, our plan for bridging through the Phase 2b COVID-19 readout rests on three main pillars: first, disciplined cost management; second, the continued push for non-dilutive funding; and then finally, I suppose, preserving optionality around the timing and financial terms tied to any future capital raises. On that first point, cost management, we keep prioritizing spend against our major value drivers, clearly the BARDA-funded Phase 2b study, but also the entire young norovirus program; we've taken steps to keep corporate spending very tightly controlled throughout this readout window, just to make sure that, again, we're being as efficient as possible on everything not directly tied to these programs. On the topic of non-dilutive capital, the BARDA contract directly funds the execution and data analysis of the Phase 2b study, and James has walked us through the details of that. Alongside that, we're pursuing co-development partnerships, licensing, public health grant funding, and Steven has gone extensively through the status of those efforts. Finally, on financing flexibility, we have access to a $25 million equity line of credit with Lincoln Park Capital. That's one of the tools available to us; it isn't a financing plan in and of itself, and our intent is to keep using that equity line very selectively and only to the extent it's needed to maintain flexibility into these COVID study readouts.

David Carey

executive
#55

Thanks, Jeroen. One more point about that: suppose you did sell shares under the Lincoln Park agreement — how much more could that extend your cash runway, including the $420,000?

Jeroen Grasman

executive
#56

Like I mentioned earlier, that credit facility totals $25 million, and if we drew down the whole thing, it could potentially push our cash runway out to 2028. As I just mentioned, we're still going after other sources of capital that don't dilute shareholders, treating that as our top priority, and we'll draw on this credit line only carefully as we weigh every funding option available to us.

David Carey

executive
#57

Thanks, Jeroen. For the next question, I suppose it could go to either Jeroen or Steven: what's the reason Vaxart is hiring a VP of Technical Operations at the same time as it's cutting R&D spending by a significant amount?

Jeroen Grasman

executive
#58

Thank you — I'll handle this question too. Once more, we recognize and value the fact that bringing on executives while cash is this tight naturally invites scrutiny; we're clearly in a position where capital has to be managed with great care, and we hear our shareholders' concerns. For us to move our pipeline forward, drawing experienced leaders is critical, and every appointment is made with considerable care, keeping the company's resources and the constraints around them, along with our strategic priorities, squarely in view. I want to bring back to mind the terms of the Dynavax agreement, which we disclosed in the November 2025 Form 10-Q. That agreement with Dynavax includes a technology transfer requiring us to disclose and transfer Vaxart know-how. It refers to transferring master batch records for manufacture of Phase 2b materials. It refers to analytical method transfer; it refers to the need for all of this to be completed on a timeline that Dynavax, acting in good faith, determines is necessary for initiation of manufacture of Phase 3 clinical trial material. All of that means we must be prepared for that specific step. Even with capital constrained, we have to ensure our technical operations team has the capabilities needed to make a successful future potential opt-in possible, even at a moment when capital here is constrained.

David Carey

executive
#59

Thanks, Jeroen. We’re almost out of time, but here’s one more follow-up tied to that, and Steven, you can handle this one: would you talk about what management intends to do on the manufacturing side, given recent hires like the new CTO?

Steven Lo

executive
#60

Okay, building on what Jeroen just said, this ties into another question about bringing on our Chief Technology Officer, Todd Lehman. Let me start by noting that all our clinical manufacturing happens right here in South San Francisco. We see that as a competitive advantage. Actually, one factor that let us keep running our study with BARDA was our ability to clinically manufacture a different strain. We moved from XBB to KP.2 in roughly a quarter, and BARDA was genuinely pleased about that. Having manufacturing in-house is a competitive advantage, and beyond that, having production based in the United States matters a great deal too, particularly when the US government is funding us. Looking ahead, as Jeroen just pointed out, part of what we're obligated to do involves proceeding with tech transfer, and having the experience and capabilities of someone like Todd, who across his career at large pharma and also at Dynavax has been involved in clinical manufacturing, has in fact overseen tech transfer, has in fact overseen Phase 3 manufacturing, and has overseen commercial manufacturing, means from where we sit, bringing in a person with that background also places us in a competitive position going forward. Once again, quite often the emphasis really falls on our know-how and capability within the manufacturing group.

David Carey

executive
#61

Thank you, Steven. We’ve just about reached the end of our time, so I’ll hand things back to you for any closing remarks.

Steven Lo

executive
#62

Thanks so much, everyone, for being with us today and for the questions you raised. We definitely managed to use the full hour, and we truly appreciate how engaged you were. Our third quarter shows ongoing momentum in our clinical programs, our pipeline, and governance — among the highlights: we locked in norovirus patent protection across Europe running through 2036, we published peer-reviewed pre-clinical data demonstrating 100% protection against the lethal H5N1 avian flu, we are steadily moving our Phase 2b COVID-19 trial forward as we head toward our mid-year 2027 milestone, and we welcomed Dr. Rocky Bono to the board, where he will lead our Stockholder Engagement Committee. A single mission drives everything we do: removing the obstacles posed by traditional needle-based vaccines through stable, easy-to-distribute oral pill vaccines that deliver mucosal and systemic protection right at the point where pathogens get in. Our sincere thanks go out to our trial participants, our investigators, and the dedicated team here at Vaxart, whose hard work makes this research possible. And thank you to our stockholders for your engagement and your continued support. We look forward to bringing you updates on our progress in the months ahead, and we wish you all a great evening.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Vaxart, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Vaxart, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Vaxart, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.